Cidara Therapeutics Inc (NASDAQ: CDTX) stock closed at $18.92 on 4/1/25 after a major decline of -12.2%. Moreover, trading volume in this decline was above average at 126% of normal. The stock has declined -19.9% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Cidara Therapeutics has a current Value Trend Rating of C (High Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Cidara Therapeutics has a poor Appreciation Score of 20 but a very high Power Rating of 94, triggering the High Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment